Bengaluru, February 5, 2026 – Strides Pharma Science Limited on Wednesday announced a key operational milestone for its US business, with its step-down subsidiary Strides Pharma Inc receiving an inspection closure report for its formulations facility at Chestnut Ridge, New York.
The inspection at the Chestnut Ridge plant was conducted between December 17 and December 23, 2025, and covered manufacturing practices along with capabilities related to drug-device combinations. The assessment also included the company’s recent filing activity in the nasal sprays segment.
Following the review of the company’s responses submitted after the inspection, the facility has now received confirmation that the inspection has been formally closed. This outcome clears the site for continued and future manufacturing activity for the US market.
Strengthening US Market Operations
The Chestnut Ridge facility plays a strategic role in Strides’ US operations. The plant manufactures a wide range of dosage forms including liquids, gels, hormones, modified-release products and controlled substances, supporting several current and upcoming products targeted at the US market.The successful closure of the inspection, including coverage of drug-device combination capabilities, is expected to strengthen Strides’ position in complex dosage segments such as nasal sprays. The development is also seen as supportive of the company’s near-term growth plans in regulated markets.
Strategic Focus on Complex Products
Strides continues to focus on difficult-to-manufacture products across global markets. The company’s manufacturing footprint spans India, Italy, Kenya and the United States, enabling it to service regulated, institutional and donor-funded markets across more than 100 countries.The latest development at the US facility adds to the company’s efforts to expand its portfolio in specialised delivery systems while maintaining consistent operational standards across geographies.
About the Company
Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India, and is listed on the BSE and NSE. The company has a strong presence in regulated markets and follows an “in Africa for Africa” strategy alongside an institutional business catering to donor-funded programmes. Strides’ diversified manufacturing network and focus on complex products remain central to its long-term growth strategy.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.